NYIPLA Presidents' Forum: The Impact of the Inflation Reduction Act and Other Policies on the Pharmaceutical Industry

This President’s Forum will bring together thought leaders to consider the impact of the Inflation
Reduction Act (IRA) and other policies, such as price controls and IP waivers, on the pharmaceutical
industry. We will discuss the public policy and economic reasoning both for and against the IRA and
similar policies. We will address the IRA’s impact on innovation and drug development, as well as
potential consequences for end consumers. We will also consider how the IRA and similar policies
could impact investments in the pharmaceutical sector.
This Forum will provide different perspectives from legal experts on these crucial issues, and the NYIPLA
hopes this Forum can help move all parties closer to agreement.

SPEAKERS: 

• Richard Frank, Leonard Schaeffer Chair in Economic Studies, Director of Schaffer Initiative on Health Policy, The Brookings Institution 
• Henry Hadad, Senior Vice President and Deputy General Counsel, Bristol Myers Squibb
• Karin Hessler, General Counsel, Association for Accessible Medicines
• Anna Makki, Managing Director, Marathon Asset Management

This Presidents' Forum is open to NYIPLA members ONLY.